These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28966198)

  • 1. Reducing Carbapenem Exposure: Extended-Spectrum β-Lactamase Catheter-Associated Urinary Tract Infection Management.
    Holt S; Grant M; Thompson-Brazill KA
    Crit Care Nurse; 2017 Oct; 37(5):78-84. PubMed ID: 28966198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
    Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
    BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
    Aslan AT; Akova M
    Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
    [No Abstract]   [Full Text] [Related]  

  • 4. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Asakura T; Ikeda M; Nakamura A; Kodera S
    Int J Infect Dis; 2014 Dec; 29():91-5. PubMed ID: 25461239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
    Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
    Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials.
    Trivedi M; Patel V; Soman R; Rodriguez C; Singhal T
    J Assoc Physicians India; 2012 Aug; 60():28-30. PubMed ID: 23405518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-carbapenem therapy of urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae.
    de La Blanchardière A; Dargère S; Guérin F; Daurel C; Saint-Lorant G; Verdon R; Cattoir V
    Med Mal Infect; 2015 May; 45(5):169-72. PubMed ID: 25845927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients.
    Gutiérrez-Gutiérrez B; Rodríguez-Baño J
    Clin Microbiol Infect; 2019 Aug; 25(8):932-942. PubMed ID: 30986558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using β-lactam/β-lactamase inhibitors for infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae to slow the emergence of carbapenem-resistant Enterobacteriaceae.
    Watkins RR; Deresinski S
    Expert Rev Anti Infect Ther; 2017 Oct; 15(10):893-895. PubMed ID: 28914107
    [No Abstract]   [Full Text] [Related]  

  • 12. Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum Beta-lactamase producing Enterobacteriaceae in urinary isolates.
    Afridi FI; Farooqi BJ
    J Coll Physicians Surg Pak; 2012 Jun; 22(6):358-62. PubMed ID: 22630093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
    Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbapenems and alternative β-lactams for the treatment of infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae: What impact on intestinal colonisation resistance?
    Woerther PL; Lepeule R; Burdet C; Decousser JW; Ruppé É; Barbier F
    Int J Antimicrob Agents; 2018 Dec; 52(6):762-770. PubMed ID: 30176355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Antibiotic Resistance in Urinary Tract Infection Patients with Prior Urine Cultures.
    Dickstein Y; Geffen Y; Andreassen S; Leibovici L; Paul M
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4717-21. PubMed ID: 27216064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associated factors and outcomes for OXA-232 Carbapenem-resistant Enterobacteriaceae infections in a tertiary care centre in Mexico City: A case-control-control study.
    Torres-González P; Ortiz-Brizuela E; Cervera-Hernandez ME; Bobadilla-Del Valle M; Martínez-Gamboa A; Sifuentes-Osornio J; Ponce-de-Leon A
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):243-8. PubMed ID: 27519297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emergence of Extended-Spectrum β-Lactamase Urinary Tract Infections Among Hospitalized Emergency Department Patients in the United States.
    Talan DA; Takhar SS; Krishnadasan A; Mower WR; Pallin DJ; Garg M; Femling J; Rothman RE; Moore JC; Jones AE; Lovecchio F; Jui J; Steele MT; Stubbs AM; Chiang WK; Moran GJ
    Ann Emerg Med; 2021 Jan; 77(1):32-43. PubMed ID: 33131912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options?
    Harris PN; Tambyah PA; Paterson DL
    Lancet Infect Dis; 2015 Apr; 15(4):475-85. PubMed ID: 25716293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
    You JH; Kei HW; Lau WC; Wong KY; Marasinghe T; Lee N; Ip M
    J Hosp Infect; 2008 Feb; 68(2):181-3. PubMed ID: 18194826
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical outcomes of elderly patients with bloodstream infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward.
    Meini S; Laureano R; Tascini C; Arena F; Fani L; Frullini A; Passaleva MT; Roberts AT; Mannini D; Sbrana F; Ripoli A; Rossolini GM
    Eur J Intern Med; 2018 Feb; 48():50-56. PubMed ID: 29089174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.